Hologic (HOLX) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Organizational and strategic highlights

• Achieved strong execution against 2025 goals, with all business franchises larger and stronger than pre-COVID levels.

• International business transformed over the past decade, now with direct presence and above-market growth.

• Leadership team now has deep domain expertise, enhancing business development and future readiness.

Molecular diagnostics and assay adoption

• Panther install base grew from 500 in 2014 to 3,300, with over 20 assays now available.

• Focus is on increasing menu adoption; over a third of customers use four or more assays.

• Women's health assays remain the cornerstone, with new menu items like BV/CV driving growth.

• Respiratory and viral assays are expanding, with future menu additions planned.

Key product and market opportunities

• BV/CV/TV assay exceeds $100M in annual revenue and is the second-largest assay, with significant U.S. growth runway.

• Biotheranostics business nearly tripled since acquisition, with strong growth potential in breast cancer recurrence testing.

• Genius AI digital cytology platform launched internationally, addressing workforce constraints and enabling growth.